TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05152524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tigertriever 13
Description: patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
Study: NCT06264830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon-NGENUITY®(NG)-system
Description: During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard cataract operation
Description: Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cataract operation
Description: Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
Study: NCT05575063

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Healon EndoCoat
Description: Ophthalmic Viscoelastic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Healon EndoCoat
Description: Ophthalmic Viscoelastic device
Study: NCT05096884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: The beta blocker metoprolol succinate will be initiated at a starting low dose of 25 mg daily for two weeks and will be escalated if well tolerated every 2 weeks to a maximum dose of 400 mg po daily.
Study: NCT05203913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: The recommended dose for nivolumab is 480 mg administered as 30 minutes IV infusions every 28 days for 13 infusions.
Study: NCT06013969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab intravenous (i.v.) infusion
Study: NCT05810870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1611
Description: MEN1611 is a potent, orally bioavailable selective inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) with a novel structure which exhibits a strong inhibitory activity especially against the PI3K catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor MEN1611 selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin mesylate (eribulin), a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastics, suppresses microtubule growth and sequesters tubulin into nonfunctional aggregates, preventing mitotic spindle formation with subsequent G2-M stop and apoptosis.
Study: NCT05203913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: The recommended dose for nab-paclitaxel is 60 mg per square meter administered as 30 minutes IV infusions every 7 days (weekly), during the radiotherapy period.
Study: NCT06146062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells (MSC)
Description: 3 injections one week apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 injections one week apart
Study: NCT06001749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A tryptamine derivative, capsule, taken orally.
Study: NCT05403268

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DeltaScan
Description: Twice daily DeltaScan observations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeltaScan
Description: Twice daily DeltaScan observations
Study: NCT05811949

Intervention type: DRUG
Intervention: Dimethyl Fumarate 240 MG [Tecfidera]
Description: DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.

Intervention type: DRUG
Intervention: Dimethyl Fumarate 240 MG [Tecfidera]
Description: DMF is admnistered to RRMS patients who are candidates for treatment according to clinical practice at a dosage of 120 mg twice daily, increased to 240 mg twice daily after 7 days.
Study: NCT04905407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Tamibarotene tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Tamibarotene tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Tamibarotene tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine injection will be administered per dose and schedule specified in the arm.
Study: NCT04441515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipod with music
Description: music of patient's preference provided 2 hours daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ipod with books to listen
Description: 2 hours of daily listening to books

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ipod only with usual care
Description: participants given device only
Study: NCT06140225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACER Application
Description: It is an application that allows the recording of the sports activities performed. It includes alerts and reminders that allow you to plan your sports practice in advance, as well as a weekly record of the activities and kilometers run, and a comparative analysis with the previous week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapMyWalk Application
Description: It is an application that promotes the practice of physical activity by recording the sports activities that the subject performs, as well as the dissemination of the same in social networks and participation in challenges available to users around the world. In addition, this application includes reminders of physical activity and personal achievements to encourage the practice of sports.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strava Application
Description: It is an application that promotes sports practice, nutritional habits and the necessary rest. Nutrition and sleep will be introduced as variables that favor a healthy lifestyle.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POKEMON GO APPLICATION
Description: It is a mobile game that favors the increase of physical activity because it is necessary to walk to achieve the proposed objectives.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JEFIT APPLICATION
Description: It is an app whose goal is to be a support in training of strength-resistance training. Setting a specific goal, with a full databaseover of exercises to perform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FITBIT-FLEX APPLICATION
Description: It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEIZU BONG 2S APPLICATION
Description: It is a physical activity wereable. It acts as a witness to physical activity and transmits the data to the computer or smartphone.
Study: NCT06223269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin Xenotransplant
Description: realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically engineered, alpha-1,3-galactosyltransferase knock-out (GalT-KO) porcine (Sus scrofa) donors under aseptic conditions.~realSKIN® is topically applied to a surgically prepared wound bed via sutures or staples and may be trimmed to fit the shape and size of the wound area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft(ing)
Description: Autograft(ing) is the current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin, i.e. autologous (self) skin harvesting, from an uninjured site on the patient and using it to cover the original burn wound.
Study: NCT06193239

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OWL-EVO1
Description: EVOC probe
Study: NCT05515237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grade 2-5 CI Therapy + Sensory Components
Description: All participants will receive CI Therapy + Sensory Components over a 2-3 weeks time frame. The treatment intervention will apply all CI Therapy treatment components to include: 1) a behavioral set of techniques called the Transfer Package (TP) to promote carry-over of skills that were gained in the laboratory into the participant's life situation, 2) the use of motor training called shaping to make progress in small approximations 3) the use by the participant of a mitt on the less-affected hand to encourage use of the more-affected hand and 4) home skills and home work will be provided each day for at least 30 minutes. Sensory component training strategies will be added to stimulate sensory input through the more-affected arm an dhand as well as to train sensory discrimination skills.
Study: NCT05559047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse novel CPAP mask
Description: Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).~Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phillips Respironics Nuance
Description: Participants will follow instructions to set up and put on the Respironics Nuance, traditional nasal mask. Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Study: NCT06228937

Intervention type: OTHER
Intervention: analysis of a sample of stool
Description: typing of the gut microbiota from a stool sample

Intervention type: OTHER
Intervention: analysis of a sample of stool
Description: typing of the gut microbiota from a stool sample
Study: NCT05402501

Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention program Leef! met MS
Description: The lifestyle program consists of a three-months intensive program, followed by a 21-months 'inspiration' program with occasional meetings.
Study: NCT06361251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC14_4osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC14). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYONOVE (EC05osc)
Description: The prototype is a variant version from that of a CE marked MD already commercialized (Cryobeauty mains, Cryobeauty Pharma SAS, France) which produces a cryogenic spray sequence (EC05). The prototype is intended to treat pigmented spots of the face (PIH spots and senile and solar lentigos).
Study: NCT03804905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-cost Medications
Description: Patients will be connected to Trillium Health Partners outpatient pharmacy, and they will be given an information sheet with further details. The patients will get free access to diabetes, blood pressure and cholesterol medications and for glucose test strips. They can attend the pharmacy in person or arrange for home delivery.
Study: NCT06405529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge
Description: During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and intensive mobilization protocol at the ICU and Rehabilitation post-hospital discharge
Description: During hospitalization in the ICU and ward, you will perform 30 to 60 minutes of exercises per day, according to the IMS scale.~After hospital discharge, participation in a supervised exercise program twice a week for 8 weeks at the Rehabilitation Center - CER of the Hospital das Clínicas of the Faculty of Medicine of Ribeirão Preto.
Study: NCT05328622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aqueduct Contingency Management Platform
Description: All individuals who consent to participate will engage with the Aqueduct contingency management system. Once participants are enrolled, they accumulate points in Aqueduct for each prenatal/postpartum appointment they attend. They also earn points for attending pregnancy and birth related classes, monitoring their health (e.g., blood sugar, blood pressure), and taking prescribed medications. Participants then redeem their points for money on a Visa gift card.~Enrolled participants also receive daily text messages that contain motivational and mini-educational content regarding pregnancy from trusted sources such as the American College of Obstetricians and Gynecologists, Evidence Based Birth, and Postpartum Support International. These texts serve as reminders to participants to remain engaged in their pregnancy care.
Study: NCT05260242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disparities Conversation
Description: The study intervention will be a scripted interaction delivered by an anesthesia healthcare provider to an individual patient admitted to the labor/delivery unit for labor epidural placement and obstetric care. The discussion will highlight current data relating to healthcare disparities in obstetric anesthesia care within underserved groups and will explain various aspects of obstetric anesthesia care in a culturally-sensitive manner.
Study: NCT06571799

Intervention type: OTHER
Group type: OTHER
Intervention: BENEV Exosome Regenerative Complex+
Description: BENEV Exosome Regenerative Complex+® is an intensive dual-action complex formulated to absorb quickly into the skin and scalp delivering the concentrated power of stem cell derived lyophilized exosomes, potent growth factors, peptides, coenzymes, minerals, amino acids and vitamins.
Study: NCT06571877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with manipulation of the energy density
Description: Dietary intervention with manipulation of the energy density either during breakfast or during lunch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention with manipulation of the energy density
Description: Dietary intervention with manipulation of the energy density either during breakfast or during lunch
Study: NCT06011733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
Study: NCT06199778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: 1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: Based on this, the patients in the observation group were given nutrition support with Intermittent Oro-esophageal Tube Feeding (Medical Device No. 20010234, developed by the Swallowing Disorders Research Institute of Zhengzhou University). The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube feeding
Description: The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reserpine
Description: Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reserpine
Description: Reserpine was administered to patients to nourish their nerves, with frequency based on their condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: The levofloxacin was administered to patients as antibiotic treatment, with frequency based on their condition.
Study: NCT05908760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 ReHaler
Description: The ReHaler captures expired CO2, which is then re-inhaled. The net effect is a transient increase in CO2.
Study: NCT05526170

Intervention type: DEVICE
Intervention: Devices for long-term monitoring of objective and subjective parameters of the body
Description: Patients will use a 1-lead Holter ECG (Bittium Faros) for heart rhythm and physical activity analysis, a wearable wrist-worn device with photoplethysmography and 6-lead ECG for heart rhythm analysis, a sleep tracking mat (Withings sleep analyser) for sleep analysis, a smartphone with triggers application for entering the subjective triggers (stress, coffee, alcohol intake and others), a 48-hour ambulatory blood pressure monitor for 2 days and a regular blood pressure monitor for up to 5 days. Patients will be monitored for up to 7 days with the described system of devices. In addition, patients will receive investigations of heart echocardiography, laboratory tests and surveys to evaluate the system and the use of acquired information.
Study: NCT05864469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week psychosocial dyadic intervention
Description: Comprising six weekly 60-min telephone-based sessions, followed by two weekly and two bi-weekly telephone follow-ups.
Study: NCT05713487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventive treatment group
Description: each athlete belonging to the preventive treatment group performed the protocol of preventive treatment 2 times a week, before or after the training session for five months
Study: NCT05536791

Intervention type: DRUG
Intervention: Dabigatran Etexilate (DE)
Description: Dabigatran Etexilate (DE)
Study: NCT06100120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Placement of osteointegrated implants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Placement of osteointegrated implants
Study: NCT05175157

Intervention type: OTHER
Intervention: Gut Fellings questionnaire
Description: Answer the Gut Fellings questionnaire

Intervention type: OTHER
Intervention: Gut Fellings questionnaire
Description: Answer the Gut Fellings questionnaire
Study: NCT06525012

Intervention type: OTHER
Intervention: Usual patient care for patients hospitalized for subarachnoid hemorrhage of aneurysmal origin
Description: During hospitalization (2013-2021), patients were managed after multidisciplinary consultation in accordance with national recommendations between resuscitators, neurosurgeons and neuroradiologists, depending on the severity of the initial management and the patient's comorbidities, either by interventional radiology, neurosurgery or medical treatment.